skip to Main Content
RallyBio Conference Room

RallyBio In-Licensing Potential First-In-Class Antibody from Sanofi.

RallyBio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company, today announced that it has obtained worldwide exclusive rights to Sanofi’s KY1066, a preclinical potentially first-in-class antibody.

Back To Top